Acquisition Announced

Repligen acquisition of BioLife Solutions

US$1.5bn enterprise value

Announced 22 Jul 2026 · NASDAQ: BLFS · US$31.00 cash and scrip per share · 24% premium

Advisers

BioLife Solutions

Target

Financial adviser
Legal adviser
Fairness opinion

Repligen

Acquirer

Legal adviser
Representatives of Perella Weinberg and Goldman Sachs, on behalf of Repligen
Target
BioLife Solutions
Acquirer
Repligen
Target based in
United States
Buyer based in
United States
Equity value
US$1.6bn
Sector
Life Sciences
Tags
Life Sciences, Cell Therapy

In the league tables

Similar deals

All life sciences deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.